Gilead Sciences (NASDAQ:GILD) was downgraded by investment analysts at Vetr from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Wednesday. They presently have a $90.00 price objective on the biopharmaceutical company’s stock. Vetr‘s target price indicates a potential upside of 10.11% from the stock’s previous close.

GILD has been the topic of several other reports. Berenberg Bank set a $96.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Credit Suisse Group reaffirmed a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, December 7th. Zacks Investment Research cut Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. Finally, Argus cut Gilead Sciences from a “buy” rating to a “hold” rating and lifted their price objective for the company from $73.25 to $73.77 in a research report on Monday, November 13th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eighteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $85.53.

Gilead Sciences (NASDAQ GILD) traded up $1.49 during midday trading on Wednesday, hitting $81.74. The company had a trading volume of 11,158,092 shares, compared to its average volume of 8,030,000. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The company has a market capitalization of $106,750.00, a PE ratio of 9.30, a PEG ratio of -1.68 and a beta of 1.13. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. Gilead Sciences’s quarterly revenue was down 13.2% on a year-over-year basis. During the same period last year, the firm earned $2.75 earnings per share. equities analysts anticipate that Gilead Sciences will post 8.53 EPS for the current year.

In other news, EVP Gregg H. Alton sold 30,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $79.00, for a total transaction of $2,370,000.00. Following the completion of the transaction, the executive vice president now directly owns 57,114 shares in the company, valued at $4,512,006. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the transaction, the executive vice president now owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The disclosure for this sale can be found here. Insiders have sold 491,666 shares of company stock valued at $36,442,567 over the last quarter. Company insiders own 1.30% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in GILD. Welch Investments LLC purchased a new position in Gilead Sciences in the 3rd quarter worth approximately $108,000. Wealthcare Advisory Partners LLC purchased a new position in Gilead Sciences in the 3rd quarter worth approximately $133,000. Horan Capital Advisors LLC. purchased a new position in Gilead Sciences in the 3rd quarter worth approximately $144,000. Hanson & Doremus Investment Management raised its holdings in Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new position in Gilead Sciences in the 2nd quarter worth approximately $147,000. Hedge funds and other institutional investors own 75.95% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Vetr Downgrades Gilead Sciences (GILD) to Buy” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2018/01/17/vetr-downgrades-gilead-sciences-gild-to-buy.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.